Francesca Palandri: Highlighting Innovation in Rare Disease Care at EHA 2026
Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn:
“EHA 2026 – Stockholm | Myeloproliferative neoplasms
I am grateful to La Piazza Avvenimenti for the attention with which he told about my participation in the educational session ‘Modern approaches to ET and PV’, in which I talked about:
- Risk stratification
- Innovative therapies
- Multidisciplinary and patient-centered approach
That a newspaper born from the world of commerce and business dedicates space to the themes of health and innovation in rare diseases says a lot: it means recognizing that 360-degree personal care is not just about medicine, but is a value that crosses society, work, and the community.
It is a look at progress and passion, capable of holding together the interest of the community and attention to the individual: the same logic that guides good medicine.
Thanks to La Piazza Avvenimenti for this sensitivity, and thanks always to IRCCS Policlinico di Sant’Orsola – Azienda Ospedaliero Universitaria di Bologna and Alma Mater Studiorum – Università di Bologna.”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian